BAUSCH & LOMB RECEIVES CLEARANCE TO BEGIN MARKETING DIPIVEFRIN HYDROCHLORIDE OPHTHALMIC SOLUTION USP, 0.1%.

ROCHESTER, N.Y.--(BUSINESS WIRE)--June 27, 1995--Bausch & Lomb (NYSE/BOL) announced today that its U.S. Pharmaceutical Division has received clearance to begin marketing Dipivefrin Hydrochloride Ophthalmic Solution USP, 0.1%, a generic equivalent to Propine(R)(a). Dipivefrin HCI Ophthalmic Solution 0.1% is indicated for lowering intraocular pressure in patients with chronic open-angle glaucoma.

Dipivefrin HCI Ophthalmic Solution 0.1% compliments Bausch & Lomb's existing products for lowering intraocular pressure, including OptiPranolol(R) (Metipranolol 0.3% Ophthalmic Solution) and Levobunolol Hydrochloride Ophthalmic Solution, which are two ophthalmic beta-blocker solutions, and Pilostat(R) (Pilocarpine Hydrochloride Ophthalmic Solution).

Annual domestic branded and generic industry sales of Dipivefrin HCl Ophthalmic Solution 0.1% total more than $45 million.

Since November 1993, Bausch & Lomb has received a total of 25 new product authorizations, including Crolom(TM) (Cromolyn Sodium Ophthalmic Solution USP, 4%) indicated for the relief of symptoms associated with vernal conjunctivitis, a seasonal allergic eye condition, and Tobramycin Ophthalmic Solution USP, 0.3%, a widely prescribed antibiotic for superficial eye infections.

Dipivefrin HCI Ophthalmic Solution 0.1% is one of an ongoing series of new products being manufactured and marketed by Bausch & Lomb's U.S. Pharmaceutical Division headquartered in Tampa, Florida.

(a) Propine(R) is a registered trademark of Allergan Pharmaceuticals. OptiPranolol(R) is a registered trademark of Bausch & Lomb Pharmaceuticals. Pilostat(R) is a registered trademark of Bausch & Lomb Pharmaceuticals. Crolom(TM) is a trademark of Bausch & Lomb Pharmaceuticals. (C)1995 Bausch & Lomb Pharmaceuticals, Inc.

CONTACT: Bausch & Lomb

Franklin T. Jepson

716/338-6025 (office)

716/461-2534 (residence)